Category: Pharmaceuticals

Pharmaceuticals

Lilly’s Investigational Triple Agonist Retatrutide Reduces OSA Severity in Phase 3 Trial

Phase 3 TRIUMPH-1 trial data show retatrutide reduced the AHI by up to 36.1 events per hour alongside substantial weight loss.

Pharmaceuticals

Natrol Launches Ultra Sleep and Ultra Energy Supplements, Partners with Calm

The new dual-product system aims to support the 24-hour wellness cycle, accompanied by a strategic partnership with the Calm app to offer curated sleep content.

Pharmaceuticals

Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting

New poster presentation will detail self-reported outcomes in patients with narcolepsy treated with high dosages of low-sodium oxybate in the DUET study.

Prescription Drugs

Yes, GLP-1s Treat (Some) OSA, But They Also Expose Limits of Obesity-Focused Strategies

As weight-linked cases improve, the field is left to confront the patients whose condition stems from other mechanisms.

Over-the-Counter Treatments

Saline Nasal Spray Shows Efficacy in Treating Pediatric Sleep-Disordered Breathing

A new Australian study finds that a simple saline nasal spray can resolve symptoms of obstructive sleep-disordered breathing in children, potentially reducing the need for surgery and specialist care.

Emerging Compounds

Incannex Updates Clinical Pathway for Sleep Apnea Drug Candidate IHL-42X

The biopharmaceutical company will initiate a phase 2 dose-optimization study for its oral OSA therapy before advancing to a streamlined phase 3 program.